Research Library

High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.

NAFTA has become increasingly more controversial in the United States. U.S. firms and workers are best served by an examination of the agreement to improve and modernize the relationship and make it more equitable to all partners. This will benefit America’s economy, and that of Canada and Mexico.

Shifts in U.S. economic policy toward China could provide leverage on other issues and, at the beginning of a new administration, usefully set a tone of cooperation.

Mexico Center director Tony Payan outlines overarching principles and specific policy proposals that, with the necessary political will, can productively address complex immigration issues.

Ambassador Edward P. Djerejian, director of the Baker Institute, describes the key elements of a coherent strategy for defeating ISIS, incorporating both nearer-term strategies and long-term approaches.

Science, technology, and innovation are vital to America’s economy and workforce, and the competitiveness of U.S. industry. The authors offer five recommendations to ensure the establishment of an effective White House Office of Science and Technology Policy.

The United States has a unique opportunity to reduce the spread of disease by engaging the leaders of the G20 countries and targeting neglected diseases. Fellow Peter Hotez explains how.

The Trump administration should push for formal congressional authorization of both the ongoing operations against ISIS and any significant increase in U.S. military action in Syria, writes fellow Joe Barnes.

With growing competition from abroad, the U.S. must reform its fiscal policy to reduce debt, maximize economic efficiency — including minimizing the distortions caused by the tax system — and maintain its areas of competitive advantage.

There is broad consensus in the medical and scientific community that substance abuse should be treated as a medical and public health problem, not a crime. The authors recommend a sensible pivot from failed policies of drug prohibition toward a realistic approach to drug use.